Progression-Free Survival
Figure 1 · Panel BV-AVD_vs_N-AVD_Progression-Free_Survival
Panel BV-AVD_vs_N-AVD_Progression-Free_Survival 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Sharon M Castellino, Hongli Li, Alex F Herrera, Michael LeBlanc, Susan K Parsons, Joseph M Unger, Angela Punnett, David Hodgson, Frank G Keller, Richard A Drachtman, Adam Lamble, Christopher J Forlenza, Andrew Doan, Sarah C Rutherford, Andrew M Evens, Richard F Little, Malcolm A Smith, Bradford S Hoppe, Joo Y Song, Sonali M Smith, Jonathan W Friedberg, Kara M Kelly
J Clin Oncol 44(6) 449-454
We present a subset analysis on the adolescent cohort of the S1826 randomized phase three trial, comparing nivolumab, doxorubicin, vinblastine, dacarbazine (N-AVD) to brentuximab vedotin-AVD (BV-AVD) in newly diagnosed advanced-stage (AS, stages III and IV) classic Hodgkin lymphoma (cHL). Among 994 patients enrolled, 24% (n = 240) were age 12-17 years. The 3-year progression-free survival (PFS) was significantly higher in the N-AVD group (93% [95% CI, 87 to 96]) compared with the BV-AVD group (82% [95% CI, 73 to 88]; hazard ratio, 0.37 [95% CI, 0.17 to 0.80]). One N-AVD and two BV-AVD patients received protocol-specified residual site radiotherapy (RT). Rates of febrile neutropenia and sepsis were low in both groups. Severe immune-related adverse events were infrequent, although thyroid dysfunction was seen in 7% with N-AVD. Sensory neuropathy (grade ≥2) was more frequent with BV-AVD (14% v 7%) by clinician report. Although premature discontinuation of therapy was reported in 12 N-AVD patients and four BV-AVD patients, no PFS events were noted in the N-AVD group. Patient-reported outcomes indicated less toxicity with N-AVD. N-AVD demonstrated high 3-year PFS in adolescents with AS cHL, with minimal RT use. S1826 exemplifies the benefits of harmonized clinical trial protocols, resulting in timely access to novel agents for adolescents.
1 个 Figure · 2 个 KM 面板
Figure 1. a) 3-year Progression-Free survival (PFS) in adolescent patients with advanced stage cHL by study arm b) 3-year Progression-Free survival (PFS) in adolescent patients with Stage III cHL by study arm c) 3-year Progression-Free survival (PFS) in adolescent patients with Stage IV cHL by study arm d) 3-year Event-Free Survival by study arm, where events on N-AVD were due to non-protocol chemotherapy prior to progression (n=4); non protocol RT prior to progression (n=1) or progression of disease (n=9). With BV-AVD events were due to non-protocol chemotherapy prior to progression (n=1); non-protocol RT prior to progression (n=1) and progression of disease (n=22) and death (n=1). Note: the 95% CI for the hazard ratio (HR) is two-sided.
Figure 1 · Panel BV-AVD_vs_N-AVD_Progression-Free_Survival
Panel BV-AVD_vs_N-AVD_Progression-Free_Survival 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 1 · Panel Patients_at_Risk_Table
Panel Patients_at_Risk_Table 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。